-
Government boosts production of Remdesivir from 38 lakh to 119 lakh vials a month
With the accelerated approval of 38 additional production sites, the number of approved manufacturing sites of Remdesivir in India has gone up, from e
-
Cipla Q4 profit up 73% at Rs 412 crore
For the entire 2020-21 fiscal year, Cipla reported a consolidated net profit of Rs 2,389 crore as against Rs 1,500 crore in the previous year
-
Stocks to watch: PowerGrid InvIT, L&T, Dr Reddy’s Labs, Cipla, Macrotech Developers, TCS
Here is the list of top stocks that could be in focus on May 14.
-
Covid-19: Cipla signs pact with Eli Lilly to produce, sell COVID-19 treatment drug
Amid spiraling cases of covid-19 in the country, drug firms have been collaborating to come out with drugs to treat the highly infectious disease.
-
Best pharma stocks to buy in 2021
Aurobindo Pharma, IPCA Labs, Cadila Healthcare, Cipla, Sun Pharma, Lupin, Dr. Reddy’s Labs & Biocon are best pharma stocks to buy in 2021
-
Nifty Pharma at record highs, in for a long haul
The Nifty Pharma index closed at record highs of 13,426 gaining 1.29% on Tuesday, while the benchmark Nifty index ended below 14,300-mark at 14,296 af
-
Pharma stocks outperform as Covid-19 cases spike; what’s next?
With a rally of 2.28%, Dr Reddy’s Laboratories emerged as the top gainer in the index
-
Scaled up remdesivir production two-fold: Cipla
In view of increased demand for the drug due to a surge in COVID-19 cases, the Centre on Sunday prohibited the exports of remdesivir injection
-
These pharma stocks can deliver up to 42% returns
Aurobindo Pharma, IPCA Labs, Cadila Healthcare, Cipla, Sun Pharma, Lupin, Divi’s Labs, Dr. Reddy’s Labs & Biocon are set for structural value upgr
-
Give booster dose to your portfolio with these three pharma stocks
ICICI Securities holds a positive view on the pharmaceutical sector, citing the high possibility of growth revival in Indian formulations on a low bas
